Tome Biosciences

Biotech · Private

Programmable genomic integration platform (PING) for inserting large DNA sequences into precise chromosomal locations

tomebio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
29
0 granted · 29 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2050SAMDI TECH, INC.——
2051CORD BLOOD PLUS, INC.——
2052ViraCyte LLC——
2053Tome Biosciences——
2054Advanced Solutions Holdings, Inc.—$36M
2055CATENA BIOSCIENCES, INC.——
2056Aspen Stem Cell Institute, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 29
  • Systems, Compositions, And Methods For Targeting Liver Sinusodial Endothelial Cells (lsecs)application
  • Revision Of Genetic Material Using Direct Replacement Editingapplication
  • Revision Of Genetic Material Using Direct Replacement Editingapplication
  • Revision Of Genetic Material Using Direct Replacement Editingapplication
  • Platforms, Compositions, And Methods For In Vivo Programmable Gene Insertionapplication
  • Systems And Methods For In Vivo Programmable Gene Insertionapplication
  • Programmable Gene Insertion Using Engineered Integration Enzymesapplication
  • Pleiopluripotent Stem Cell Programmable Gene Insertionapplication
  • Ex Vivo Programmable Gene Insertionapplication
  • Systems, Compositions, And Methods For Targeting Liver Sinusodial Endothelial Cells (lsecs)application
  • Guide Rna Compositions For Programmable Gene Insertionapplication
  • Programmable Gene Insertion Compositionsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.